CLINICAL TRIALS PROFILE FOR DATSCAN
✉ Email this page to a colleague
All Clinical Trials for Datscan
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00129181 ↗ | Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease | Completed | GE Healthcare | N/A | 2005-01-01 | This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo. |
NCT00129181 ↗ | Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease | Completed | Pfizer | N/A | 2005-01-01 | This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo. |
NCT00129181 ↗ | Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease | Completed | Institute for Neurodegenerative Disorders | N/A | 2005-01-01 | This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo. |
NCT00209456 ↗ | Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia | Completed | GE Healthcare | Phase 3 | 2003-11-01 | The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical diagnosis of an independent expert consensus panel used as the standard of truth. |
NCT01141023 ↗ | Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression | Active, not recruiting | Institute for Neurodegenerative Disorders | Phase 2 | 2010-06-01 | This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. |
NCT01141023 ↗ | Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression | Active, not recruiting | Ken Marek, MD | Phase 2 | 2010-06-01 | This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Datscan
Condition Name
Clinical Trial Locations for Datscan
Trials by Country
Clinical Trial Progress for Datscan
Clinical Trial Phase
Clinical Trial Sponsors for Datscan
Sponsor Name